VMDViemed Healthcare, Inc.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though modest expectations priced in.
Priced for a decline (~−1% a year). The price demands less than its three-year revenue growth of 25% a year, expectations look modest.
In its normal range: P/E 26.1 vs a 26.7 median over 28 quarters (−2% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What VMD's price assumes
Viemed Healthcare, Inc. trades at 26.1× earnings against 25.8× for the median Medical Devices name, more expensive than its own group.
Trailing P/E · Medical Devices median 25.8 · 1.01× the median: the market pays up for this one
- Price / sales
- 1.23
Price / sales · as of 2026-Q1
- Free cash flow yield
- 8.1%
Free cash flow yield · Medical Devices median 4.5%
- Growth the price implies
- −0.78%
Growth the price implies · The price pays for −0.78% free cash flow growth a year for a decade; the business has delivered +38% a year over the last three.
Details›
- Price / bookas of 2026-Q1
- 2.45
- EV / EBITas of 2026-Q1
- 14.9
- EV / salesas of 2026-Q1
- 1.24
- Healthcare median P/E509 names
- 26.0
- Medical Devices median P/E64 names
- 25.8
- Free cash flow, trailing twelve months
- $29M
- Market capitalisation
- $361M
- 3-year revenue growth
- +25%
- 3-year free cash flow growth
- +38%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $7.22 |
| Its own P/E history, median | $9.61 |
| Its own P/E history, upper quartile | $11.31 |
| 52-week range | $6.26 – $12.35 |
| Today | $9.41 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.